Most Recent
A judge has told the law firm that has taken over a class action against Philips Electronics over recalled sleep apnea machines to take its time when amending the pleading, which he said was not the "finest piece of work" he'd ever seen.
US car giant Ford has partially succeeded in its challenge to a judgment that found it owed more than $6,800 to the lead applicant in a class action over defective PowerShift transmissions, but the High Court may ultimately decide how damages should be calculated under the Australian Consumer Law for reduction in value.
The government of India has flagged a possible special leave application if it loses its appeal of a decision finding it can't avoid a $111.3 million arbitral award in a dispute with three Mauritian companies that invested in Indian satellites because it waived its foreign state immunity.
A judge has rejected Facebook owner Meta's request to pause a case by the Australian Competition and Consumer Commission over scam cryptocurrency ads until a private criminal action by mining magnate Andrew Forrest is decided.
The Indian government has lost its bid to dodge a $111.3 million arbitral award in a dispute with three Mauritian companies that invested in Indian satellites, with a judge finging the country waived its foreign state immunity.
NAB unit NULIS Nominees was not only allowed to charge superannuation fund members fees for adviser commissions, it was "obliged" to do so, a court has heard during a class action trial over alleged conflicted remuneration.
NAB unit NULIS Nominees was “hopelessly conflicted” in continuing to charge allegedly unlawful adviser commissions to superannuation fund members, a court has heard on the first day of a class action trial.
Twenty-five barristers have joined the rank of silk in NSW, including one who represented AMP in a class action that settled for $100 million and another who is assisting the Commonwealth in its fight to recoup $325 million in excess subsidies in a dispute over generic Plavix.
A 16-year battle between the federal government and drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix has gone to the High Court.
Drug maker Sanofi-Aventis is not liable for the federal government’s losses for excess subsidies paid for the blood-thinner Plavix after an allegedly unjustified court injunction prevented the release of a generic version of the blockbuster drug, an appeals court has found.